1. Franco P. Orphan drugs: the regulatory environment. Drug Discov Today. 2013;18(3-4):163–72.
2. Haendel M, Vasilevsky N, Unni D, Bologa C, Harris N, Rehm H, et al. How many rare diseases are there? Nat Rev Drug Discov. 2020;19(2):77–8.
3. Nestler-Parr S, Korchagina D, Toumi M, Pashos CL, Blanchette C, Molsen E, et al. Challenges in research and health technology assessment of rare disease technologies: report of the ISPOR Rare Disease Special Interest Group. Value Health. 2018;21(5):493–500.
4. Schieppati A, Henter JI, Daina E, Aperia A. Why rare diseases are an important medical and social issue. Lancet. 2008;371(9629):2039–41.
5. NORD Rare Insights Report. Barriers to rare disease diagnosis, care and treatment in the US: a 30-year comparative analysis. 2020. Available from: https://rarediseases.org/wp-content/uploads/2020/11/NRD-2088-Barriers-30-Yr-Survey-Report_FNL-2.pdf (Accessed June 2 2021).
6. Dharssi S, Wong-Rieger D, Harold M, Terry S. Review of 11 national policies for rare diseases in the context of key patient needs. Orphanet J Rare Dis. 2017;12(1):63.
7. Gammie T, Lu CY, Babar ZU. Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries. PLoS One. 2015;10(10):e0140002.
8. Khosla N, Valdez R. A compilation of national plans, policies and government actions for rare diseases in 23 countries. Intractable Rare Dis Res. 2018;7(4):213–22.
9. Orphan Drug Act of 1983. Pub L. No. 97–414, 96 Stat. 2049.
10. Kimmel L, Conti RM, Volerman A, Chua KP. Pediatric Orphan Drug Indications: 2010-2018. Pediatrics. 2020;145(4).
11. Miller KL, Fermaglich LJ, Maynard J. Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases. Orphanet J Rare Dis. 2021;16(1):265.
12. Chua K-P, Kimmel LE, Conti RM. Spending For Orphan Indications Among Top-Selling Orphan Drugs Approved To Treat Common Diseases. Health Affairs. 2021;40(3):453-60.
13. IQVIA Institute for Human Data Science. Orphan drugs in the United States: rare disease innovation and cost trends through 2019. 2020. Available from: https://www.iqvia.com/insights/the-iqvia-institute/reports/orphan-drugs-in-the-united-states-rare-disease-innovation-and-cost-trends-through-2019 (Accessed June 5 2021).
14. Every Life Foundation for Rare Diseases. The national economic burden of rare disease study. 2021. Available from: https://everylifefoundation.org/burden-study/ (Accessed May 29 2021).
15. U.S. Department of Health and Human Services. Guidlines for regulatory impact analysis. 2016. Available from: https://aspe.hhs.gov/system/files/pdf/242926/HHS_RIAGuidance.pdf (Accessed June 14 2021).
16. Milken Institute. The costs of chronic disease in the US. 2018. Available from: https://milkeninstitute.org/sites/default/files/reports-pdf/ChronicDiseases-HighRes-FINAL_2.pdf (Accessed June 14 2021).
17. NORD. Rare disease FAQ document. 2019. Available from: https://rarediseases.org/wp-content/uploads/2019/01/RDD-FAQ-2019.pdf (Accessed June 23 2021).
18. Angelis A, Tordrup D, Kanavos P. Socio-economic burden of rare diseases: A systematic review of cost of illness evidence. Health Policy. 2015;119(7):964-79.
19. von der Lippe C, Diesen PS, Feragen KB. Living with a rare disorder: a systematic review of the qualitative literature. Molecular Genetics & Genomic Medicine. 2017;5(6):758–73.
20. Handfield R, Feldstein J. Insurance companies' perspectives on the orphan drug pipeline. Am Health Drug Benefits. 2013 Nov;6(9):589–98. PMID: 24991385; PMCID: PMC4046481.
21. Chambers JD, Panzer AD, Kim DD, Margaretos NM, Neuman PJ. Variation in US private health plans’ coverage of orphan drugs. Am J Manag Care. 2019;25(10):508–12.
22. Garrison LP, Jackson T, Paul D, Kenston M. Value-based pricing for emerging gene therapies: the economic case for a higher cost-effectiveness threshold. J Manag Care Spec Pharm. 2019;25(7):793–9.
23. Schlander M, Garattini S, Holm S, Kolominsky-Rabas P, Nord E, Persson U, et al. Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders. J Comp Eff Res. 2014;3(4):399–422.
24. US Food and Drug Administration. Orphan products grants program. 2020. Avaiable from: https://www.fda.gov/industry/developing-products-rare-diseases-conditions/orphan-products-grants-program (Accessed June 14 2021).
25. US Food and Drug Administration. Rare pediatric disease priority review vouchers: draft guidance for industry. 2019. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/rare-pediatric-disease-priority-review-vouchers (Accessed June 14 2021).